Sue Hohenleitner
Chief Financial OfficerMs. Sue Hohenleitner is Chief Financial Officer of Ardelyx, Inc. from November 4, 2025. Ms. Hohenleitner has a demonstrated track record of driving organizational transformation, building financial strength and driving sustainable growth across commercial and development-stage products. Ms. Hohenleitner most recently served as the Vice President and Chief Financial Officer of Johnson & Johnson (J&J) Innovative Medicine North America (NA), leading financial strategies for a 36 billion commercial business. Prior to joining Ardelyx, Ms. Hohenleitner enjoyed a 28-year career at J&J where she led multiple finance organizations in areas such as supply chain, innovation, commercial, business development, investor relations, acquisitions and divestitures and finance planning and analysis. As VP and CFO of J&J Innovative Medicine NA, Ms. Hohenleitner led a number of strategic initiatives that resulted in greater efficiencies, effectiveness and funding for growth. Ms. Hohenleitner was also a critical partner during the acquisition of two significant deals which resulted in successful commercial launches. Ms. Hohenleitner is a Certified Public Accountant in the Commonwealth of Pennsylvania and a Certified Management Accountant. She earned a Bachelor of Science in Accounting from La Salle University and a Master of Business Administration from Villanova University. Ms. Hohenleitner was named a Top 25 CFO in Biotech by Business & Investing.
Positions
- Company NameArdelyx, Inc.Stock CodeARDXPositionChief Financial OfficerColleagues
- MGMichael G. RaabPresident, CEO & Director
- DMDavid M. MottIndependent Chairman of the Board
- JBJohn BishopChief Technical & Quality Officer
- JRJoseph ReillySenior VP of Finance & Principal Accounting Officer
- LMLisa M. CaperelliSenior Vice President of Investor Relations and Corporate Communications
- RJRichard J. RodgersIndependent Director
- WCWilliam Charles A. BertrandIndependent Director
- RBRobert B. BazemoreIndependent Director
